• About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • CD30 CAR-T Cell Therapy
    • Manufacturing
  • Pipeline
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • TT11 CD30 CAR Ts
    • TT11 CD30 CAR Ts + Nivolumab
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

What are you looking for?

Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
Tessa Therapeutics – Cancer Immunotherapy Treatments
  • About Us
    • Overview
    • Our Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Cell Manufacturing Advisory Board
    • Strategic Partners
  • Technology
    • Allogeneic Cell Therapy Platform
    • Oncolytic Virus Combinations
    • CD30 CAR-T Cell Therapy
    • Manufacturing
  • Pipeline
    • TT11X Allogeneic CD30 CAR EBVSTs
    • TT16 HER2 CAR Ts + CAdVEC
    • TT11 CD30 CAR Ts
    • TT11 CD30 CAR Ts + Nivolumab
    • Expanded Access
    • Scientific Publications
  • Investors & Media
    • Press Releases & Events
    • Interviews
  • Careers
  • Contact Us

Interview Series | In Pursuit Of Cancer Cure: Conversations With Immunotherapy Advocates – Dr Jonathan Maltzman

by tessathe on September 20, 2019 in news-videos

<< Back to Press Releases & Events

Previous Reading
Industry Perspectives from Tessa Therapeutics Board Member, Dr Göran Ando, on the Potential of Cell Therapy
Next Reading
Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020
  • ABOUT US
  • TECHNOLOGY
  • PIPELINE
  • PRESS RELEASES & EVENTS
  • CAREERS
  • CONTACT US

SITEMAP          PRIVACY POLICY

© 2021 Tessa Therapeutics Ltd. All rights reserved.